Moreover, site-specific N-glycosylation of plasma carcinoembryonic antigen (CEA) alters with CRC progression, affecting its molecular behavior and clinical utility as a biomarker [95]. The gene discussed is CEACAM5; the disease is colorectal carcinoma.